Navigation Links
Osteotech Secures 10-Year Tissue Supply Agreement
Date:11/4/2009

de variety of advanced biologics with unique regenerative qualities and healing properties."

"At CTS, we strive to be on the forefront of new graft development and we believe Osteotech's commitment to developing new technology that can leverage the gift of life supports our goal. We look forward to our expanded relationship with Osteotech," said David Smith, M.D., Chief Executive Officer of Community Tissue Services.

About Community Tissue Services

CTS is a quality and ethical non-profit provider of services to recipients, donor families, medical communities, and community partners through the respectful recovery, processing and distribution of tissue grafts. CTS, an accredited member of the American Association of Tissue Banks, is one of the largest tissue banks in the United States and operates regional offices in California, Texas, Indiana, Tennessee, Pennsylvania, Oregon and Ohio, and two satellite offices in Idaho and Oregon. For more information on CTS, visit www.communitytissue.org or call 937-461-3364.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at www.osteotech.com.

Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that th
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
7. Osteotech to Present at the Sidoti Conference in New York
8. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
9. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
10. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
11. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...eDesignC or p.(IDC)announcedtodaythatDr.BruceL.A.C...successfultrackrec or dinbiotechnologyexecutiveman...oGenetics,inSeattle,WAandChiefScientificOfficeratN...p://www.newscom.com/cgi-bin/prnh/20091123/SF15228 ...eOfficercommented,"IamdelightedtowelcomeDr.BruceCa...
(Date:11/20/2009)..., , , , , , , , ...of scientists from Washington University in St. Lo... Laboratory and Iowa State University has finished... Click here for more information. , , ... , , , , , , , , , ...
(Date:11/20/2009)... Karolinska Development AB today,a...as entered into a,co-investment agreement with the...y Karolinska Development and used to invest in the... and medical technology companies. EIF,has agreed ...The agreement,represents EIF,s largest single inve...
(Date:11/19/2009).../ -- Danish Prince Joachim inaugurated the DONG En...dborg, Denmark, on Wednesday, November 18. The fac...generation ethanol demonstration biorefineries. Ge...,s innovative process for converting straw to fuel...o market with commercial enzymes for converting ce...
Breaking Biology Technology:Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2
..., Calif. - Lawrence Livermore National Laboratory ... a solid as it evolves on the ultra-fast timescale...FEL) pulses, the team, led by Anton Barty, is able... formation, phase separation, rapid fluctuations i...ironments. Other Livermore scientists include Mich...
...Colo., June 23 Replidyne, Inc.,(Nasdaq: RDYN ) t...s license,agreement with Asubio Pharma Co., Ltd. f... with this decision, the Company also announced th...bio Pharma Co., Ltd. and Nippon,Soda Co. Ltd. for ... as a,result of the Company being unable to secure...
....-based Biorepositories Event for the Pharmaceutic...s, INDIANAPOLIS, June 23 BioStorage Technologies...materials storage, sample,management and cold chai...hip of Institute for International Research,s (IIR...sed event for the pharmaceutical and,biotech indus...
Other Biology Technology:A look into the nanoscale 2Replidyne Terminates Faropenem Agreements 2Replidyne Terminates Faropenem Agreements 3BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008 2
(Date:11/23/2009)...e highest resolution images of peptides attaching ...rstanding how biomolecules manipulate the growth c... for kidney stones using biomolecules. , The res... of the journal Proceedings of the National Acade...th mineral surfaces by accelerating, switching and...
(Date:11/23/2009)...sity of Alabama at Birmingham (UAB) researchers sh...ical conditions (co-morbidity) do not explain the ...s compared to Caucasians who also have colon cance...r , a journal of the American Cancer Society. , ...bidity are independent predictors of poor survival...
(Date:11/23/2009)...unprecedented detail how the ribosome interacts wi...ide them toward their destination in biological ce...fitting (MDFF) to examine the interaction of the r... The first study, in Proceedings of the National...ling between the ribosome and an elongation factor...
Breaking Biology News(10 mins):Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3China Biologic Products to Attend at Susquehannas Third Annual Beijing Management Summit 13968 1China Biologic Products to Attend at Susquehannas Third Annual Beijing Management Summit 13968 2China Biologic Products to Attend at Susquehannas Third Annual Beijing Management Summit 13968 3Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single Stranded RNAi Technology 56731 1Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single Stranded RNAi Technology 56731 2Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single Stranded RNAi Technology 56731 3Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single Stranded RNAi Technology 56731 4Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single Stranded RNAi Technology 56731 5Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single Stranded RNAi Technology 56731 6NovaBay Launches Clinical Study for Non Antibiotic Treatment of Impetigo One of the Most Common Skin Infections 4960 1NovaBay Launches Clinical Study for Non Antibiotic Treatment of Impetigo One of the Most Common Skin Infections 4960 2NovaBay Launches Clinical Study for Non Antibiotic Treatment of Impetigo One of the Most Common Skin Infections 4960 3NovaBay Launches Clinical Study for Non Antibiotic Treatment of Impetigo One of the Most Common Skin Infections 4960 4
...our mate,s rendition of Marvin Gaye,s "Let,s Get i...ther times? A songbird study conducted by Emory Un... that a change in hormone levels may alter the way...rain nuclei, common to all vertebrates, called the...uch as courtship, parenting and aggression depend ...
...R, Mich.---Scientists and news organizations typic...uring epidemics, but research at the University of...ions lurking in large numbers of people are the ke...lly fatal infectious disease: cholera. , Using a ...researchers and their collaborators came up with r...
...has become one of the most widely used medications..., fevers, inflammation, and blood clotting. In ani...t atherosclerosis, though none of its known mechan...a new study, though, researchers have uncovered th...prevent arterial plaque buildup. , Using cell cu...
Other Biology News:Is that song sexy or just so-so? 2Hidden infections crucial to understanding, controlling disease outbreaks 2Hidden infections crucial to understanding, controlling disease outbreaks 3
Cryopreservation medium, preadipocytes from Zen-Bio, Inc.
5X MEGAscript® T7 Kit from Ambion
Mouse Anti-Rad 51C Monoclonal Antibody, Unconjugated, Clone 2H11/6 from ABR-Affinity BioReagents
Flexi Rabbit Reticulocyte Lysate System from Promega
Biology Products: